Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Phase II AMG 386 and Paclitaxel Combination Trial

April 26th 2011

Analysis of the Phase II AMG 386 and Paclitaxel Combination Trial

FDA Approves New Test for HPV

April 20th 2011

Cervical cancer affects about 470,000 women each year and now the disease has a new tool to combat its spread

March Net Guides: Ovarian Cancer

March 31st 2011

Useful Online Resources and Clinical Trials for Ovarian Cancer

Lymph Nodes Overlooked in Ovarian Cancer Patients

March 30th 2011

Women with early-stage ovarian cancer were nearly twice as likely to die if they did not have recommended staging biopsies of pelvic and aortic lymph nodes

Dr. Tew Evaluates Avastin Treatment in Ovarian Cancer

March 24th 2011

William P. Tew, MD, a Gynecologic Medical Oncologist at Memorial Sloan-Kettering Cancer Center in New York, evaluates bevacizumab (Avastin) as a treatment for women with ovarian cancer

Net Guides: Ovarian Cancer

March 10th 2011

Useful Online Resources and Clinical Trials for Ovarian Cancer

Technology for the Taking at Research Hub in Scotland

March 9th 2011

The University of Glasgow will begin offering medical and scientific research findings, including cancer-related discoveries, to businesses and entrepreneurs free of charge

Biomarkers in Ovarian Cancer: Early Detection and Chemoresistance

March 4th 2011

Worldwide, there are ~204,000 new cases of ovarian cancer each year, accounting for 4% of cancers diagnosed in women.

Ovarian Cancer Screening Not Very Effective

March 4th 2011

Screening for ovarian cancer offers limited value, especially when accounting for the disease's biological diversity.

HRT Linked with Breast and Ovarian Cancers

July 12th 2010

Two separate studies show the relationship between hormone replacement therapy and women's cancers.

Judge Rules Myriad Cannot Patent BRCA1 and BRCA2-Genes

April 4th 2010

A US district court invalidated 7 of 23 of Myriad Genetics, Inc's patents on the BRCA1 and BRCA2 genes, which confer an increased risk of developing breast, ovarian, and prostate cancers.